Dow Jones
33.891,02 -34,99 (-0,10%) Nasdaq
11.887,45 -119,50 (-1,00%) Nikkei 225
27.754,36 +60,71 (+0,22%) EUR/USD
1,0743 +0,0013 (+0,12%) BTC-EUR
21.297,56 -219,96 (-1,02%) CMC Crypto 200
524,82 -0,32 (-0,06%)
Genetic Technologies Limited (0A4N.L)
| Chiusura precedente | 1,8200 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,88 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,6000 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update. The innovation and development of this test is inspired by direct response and feedback from the payer conversations such as insurance providers, employers, and healthcare providers. There is an unmet need to develop a unique single saliva risk asses
- GlobeNewswire
Genetic Technologies Announces $5 Million Registered Direct Offering
MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 3,846,155 American Depositary Shares (“ADSs”) (or ADS equivalent in lieu thereof), eac
- GlobeNewswire
GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer
MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer. Combined with other
